Opendata, web and dolomites

BADGER SIGNED

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BADGER project word cloud

Explore the words cloud of the BADGER project. It provides you a very rough idea of what is the project "BADGER" about.

gt    line    service    patient    paradigm    accuracy    provides    strains    resistant    clinicians    pharmaceutical    misuse    amr    foundation    causing    assay    combination    patients    diagnoses    ill    time    designed    micro    broad    treatment    antibiotics    break    settings    smartly    clinical    intend    date    mic    prescribing    commercializing    healthcare    critically    antimicrobial    inappropriate    readily    sepsis    calorimetry    sold    daily    calscreenertm    packaged    sensitivity    diagnostic    validate    badger    clinically    correct    lay    decisions    rapid    introduce    bioenergetics    assays    isothermal    near    redefine    meet    antibiotic    multichannel    calorimetric    symcel    ast    diagnostics    pure    stewardship    susceptibility    lack    cellular    perform    efficient    infections    segment    commercial    personalized    hetero    setting    validating    combat    cell    extensively    first    tools    resistance    solution    accurate    tool    vitro    specificity    contributes    device    though    suitable    speed    overuse   

Project "BADGER" data sheet

The following table provides information about the project.

Coordinator
SYMCEL AB 

Organization address
address: DOMNARVSGATAN 4
city: SPANGA
postcode: 163 53
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://symcel.com/h2020-ast-combination-testing/
 Total cost 3˙572˙567 €
 EC max contribution 3˙572˙567 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYMCEL AB SE (SPANGA) coordinator 3˙572˙567.00

Map

 Project objective

SymCel provides a novel cell-based assay tool for real-time cellular bioenergetics measurements. Our key product, the calScreenerTM, is the first multichannel calorimetric system specifically developed for cell-based assays, which to date has been sold to the pharmaceutical research segment only. Even though calorimetry is a highly advanced research tool, it is considered not suitable for broad scale uptake into daily clinical practice. Through the BADGER project we intend to break this paradigm by validating and commercializing an in vitro diagnostic tool, that is based on isothermal micro calorimetry, for determining MIC for antimicrobial susceptibility testing (AST) of hetero-resistant sepsis causing strains. By providing a tool for the easy, correct and timely diagnoses of hetero-resistant and extensively resistant infections, we will redefine the commercial application segment for calorimetry systems (from pure research settings -> near patient diagnostics) and take AST to a new level of accuracy and speed. The clinical importance of AST is increasing in line with the growing concerns over antimicrobial-resistance (AMR) and the misuse of antibiotics. Lack of a rapid, low-cost and readily available solution contributes to the inappropriate prescribing and overuse of antibiotics. Clinicians are in need of an accurate and rapid diagnostic test to increase antibiotic stewardship, introduce combination treatment for critically ill patients and help combat AMR. The calScreenerTM will meet the users’ needs by providing a reliable diagnostic tool with high speed, specificity, and sensitivity in a smartly designed and packaged device with the tools available to perform testing in a near-patient setting. In all, the Phase 2 project will lay the foundation to clinically validate the calScreenerTM which will improve diagnostic decisions, provide a higher service level for patients, combat AMR and allow for more personalized and cost-efficient approaches to healthcare.

 Deliverables

List of deliverables.
Project subpage on corporate website Websites, patent fillings, videos etc. 2020-03-04 09:46:23
Ethics approval for Clinical study no. 2 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 1 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 3 Documents, reports 2020-03-04 09:46:23

Take a look to the deliverables list in detail:  detailed list of BADGER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BADGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BADGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More